Med-tech start-up on verge of FDA approval for medical implants
4D Biomaterials, a med-tech start-up based in Birmingham, is on the verge of applying for FDA approval of its 3D-printed medical implants.
The firm is developing a range of non-toxic, biodegradable devices that can be implanted in the body to stimulate the healthy healing of tissues that the body then safely reabsorbs over time.
FDA approval will be a major milestone for the technology that will open up a stream of new medical device innovations.
4D Biomaterials was spun out from the Universities of Birmingham and Warwick in April 2020, securing international partnerships within two years of its inception. It has partnered with the world leader in micro-precision 3D printers, Boston Micro Fabrication.
The company’s 3D printable resin-inks will enable medical implants to be fitted to the exact shape and dimension requirements of each patient, helping to optimise outcomes in critical applications, such as reconstructive surgery.
Since its launch during the Covid-19 pandemic, 4D Biomaterials has been backed by the British Business Bank through DSW Ventures, as well as a number of other grants to continue the development of its products.
Philip Smith, CEO at 4D Biomaterials, said: “Our mission is to transform resorbable medical devices, creating better outcomes for patients and improving health economics. Our unique technology is non-toxic and biodegradable – it safely reabsorbs in the body over time, supporting healthy growth of the patient’s own tissue and minimising the need for permanent implants or reconstructive surgery.
“Our work would not be possible without the investment we have received so far, including funding accessed through British Business Investments, particularly with the challenges we have faced as a result of the COVID-19 pandemic.
“This is the most exciting project I have ever worked on, in terms of the huge potential of our technology to make a positive impact in people’s lives.”
The company is raising investment for a Series A round of venture capital financing to continue development of its innovative products and expand pre-clinical testing. After Series A funding, the company plans to focus on rapid growth, including recruiting at senior levels and expanding its lab facilities at MediCity in Nottingham.
Dr Sophie Dale-Black, UK network director for the Midlands and the North of England at the British Business Bank, said: “The company’s technology has huge potential to improve people’s quality of life and we are pleased to be supporting their journey.
“4D Biomaterials deliver a range of unique products to the resorbable device market is a prime example of the innovation and value that businesses can bring to vital areas of our economy and society, such as healthcare.”
